Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Anju Ghangurde

Anju Ghangurde is Scrip's Deputy Asia Editor and has about two decades of experience in journalism including stints at India's mainstream financial dailies -The Economic Times, The Hindu Business Line and The Financial Express.  She covers a broad range of issues including competition and collaboration between generics and innovator firms, drug pricing and the evolving regulatory and legal framework in the region. She is also a recipient of the British Chevening Scholarship for Young Indian Journalists (2000-01) awarded by the Foreign & Commonwealth Office.
Advertisement
Set Alert for Articles By Anju Ghangurde

Latest From Anju Ghangurde

Adverse Event Assessment In India Gets Harvard-Built Tool; Will Increased Trial Activity Follow?

Against backdrop of subdued trial activity in the country and concerns about injury compensation, Indian Society for Clinical Research and Harvard's MRCT Centre offer a portal to facilitate a more objective assessment of causality of serious adverse events.

Drug Safety Clinical Trials

GSK’s Vallance On Efficiency In R&D And Entering “The Cure” Era

Dr Patrick Vallance, President R&D at GlaxoSmithKline, tells Scrip that R&D efficiency is a priority for the company and specifies increased transparency on R&D decision-making and its returns. In a wide-ranging interview, Vallance also discusses the attention GSK’s Nucala is garnering within the severe asthma space.

Research & Development Innovation

Tepid Q3 For Sun But Momentum In Specialty Build-Up

Sun Pharma reported a decline in profits for the third quarter amid dull US and India growth and ongoing investments to prepare for a larger play in the specialty segment, where it hopes to scale up with a mix of organic and inorganic additions to its portfolio.

Commercial Generic Drugs

J&J’s Stoffels On Actelion’s ‘Exquisite’ Researchers, India TB R&D Plans

J&J’s chief scientific officer Dr. Paul Stoffels tells Scrip that flexibility is a hallmark of how the company goes about its collaborations, including the new $30bn deal with Actelion. Stoffels is also hoping to progress the science for a new TB medicine via a unique collaboration in India.

Commercial Strategy

Deal Watch: Seattle Genetics Adds To Antibody-Drug Conjugate Portfolio

Looking to expand beyond Adcetris, Seattle Genetics pays $250m up front for Immunomedics' Phase I/II ADC for triple-negative breast cancer. Elsewhere in the ADC space, Swiss biotech Novimmune and South Korea's LegoChem are teaming up on a research collaboration.

Deals M & A

Five Big Picture R&D Questions For J&J’s Stoffels, Novartis’s Narasimhan

J&J’s chief scientific officer, Dr. Paul Stoffels, and Novartis’ global head of drug development and chief medical officer, Dr. Vasant Narasimhan, were both among the global industry attendees at the recent BioAsia 2017 meeting in Hyderabad. They shared with Scrip their big picture perspectives on a range of key talking points around R&D, including the cost conundrum and the next big things in the world of medicine.

Research and Development Strategies Market Intelligence
See All
Advertisement
UsernamePublicRestriction

Register